Frequency count categorized three-day average nutrient intake of GLP-1RA participants compared to dietary reference intake
This is what all the trials are showing us. But barriers to accessing these medications remain
Journal reference: Johnson B, Milstead M, Thomas O, et al
Clinicians should exercise caution in patients with a history of pancreatitis or gastroparesis, inflammatory bowel disease, other gut motility disorders, medullary thyroid carcinoma, or Multiple Endocrine Neoplasia syndrome type 2, and pause therapy when clinically indicated, such as before anesthesia
FDA Sends Warning Letters to Telehealth Companies The FDA has recently issued warnings to 30+ telehealth companies regarding the prescribing and promotion of compounded GLP-1 drugs, including semaglutide
The lead authors of the study are Mahesh Umapathysivam, MBBS, DPhil, an endocrinologist and clinical researcher at Adelaide University in Australia and a former trainee with Gloyn, and Elisa Araldi, PhD, associate professor of medicine and surgery at the University of Parma in Italy and a former trainee with Stoffel
